The prognostic value of an autophagy-related lncRNA signature in hepatocellular carcinoma

Shiming Yang1†, Yaping Zhou2,4†, Xiangxin Zhang2,3, Lu Wang5*, Jianfeng Fu4, Xiaotong Zhao2,3 and Liu Yang2,3*

Introduction
Hepatocellular carcinoma (HCC), as the most common type of liver cancer [1], with high cancer-related mortality and poor prognosis worldwide [2], makes a threat to public health. Alcohol, aflatoxin, and hepatitis can increase HCC risk, and genetic

Abstract
Background: lncRNA may be involved in the occurrence, metastasis, and chemical reaction of hepatocellular carcinoma (HCC) through various pathways associated with autophagy. Therefore, it is urgent to reveal more autophagy-related lncRNAs, explore these lncRNAs’s clinical significance, and find new targeted treatment strategies.

Methods: The corresponding data of HCC patients and autophagy genes were obtained from the TCGA database, and the human autophagy database respectively. Based on the co-expression and Cox regression analysis to construct prognostic prediction signature.

Results: Finally, a signature containing seven autophagy-related lncRNAs (PRRT3-AS1, RP11-479G22.8, RP11-73M18.8, LINC01138, CTD-2510F5.4, CTC-297N7.9, RP11-324I22.4) was constructed. Based on the risk score of signature, Overall survival (OS) curves show that the OS of high-risk patients is significantly lower than that of low-risk patients ($P = 2.292 \times 10^{-10}$), and the prognostic prediction accuracy of risk score (AUC = 0.786) is significantly higher than that of ALBI (0.532), child_pugh (0.573), AFP (0.5751), and AJCC_stage (0.631). Moreover, multivariate Cox analysis and Nomogram of risk score are indicated that the 1-year and 3-year survival rates of patients are obviously accuracy by the combined analysis of the risk score, child_pugh, age, M_stage, and Grade (The AUC of 1- and 3-years are 0.87, and 0.855). Remarkably, the 7 autophagy-related lncRNAs may participate in Spliceosome, Cell cycle, RNA transport, DNA replication, and mRNA surveillance pathway and be related to the biological process of RNA splicing and mRNA splicing.

Conclusion: In conclusion, the 7 autophagy-related lncRNAs might be promising prognostic and therapeutic targets for HCC.

Keywords: Hepatocellular carcinoma, Autophagy-related lncRNAs, The Risk prediction model
and epigenetic changes can promote malignancy [3, 4]. At present, surgical resection remains the most common treatment option for patients with HCC. Because of tumor metastasis and relapse [5], the prognosis is dissatisfying. Most patients with advanced HCC often have low 5-year survival [6]. Currently, molecular alterations of HCC have been reported in some studies [7], and those molecular mechanisms can be explored further in the diagnosis and treatment of HCC [8–10]. However, these efforts have not made a significant improvement in patient survival. Therefore, it is necessary to identify more potential biomarkers that may be related to HCC carcinogenesis.

As a highly selective quality control, mechanism autophagy is the key to maintaining homeostasis in physiological and pathological conditions [11], such as adapting to metabolic stress, removing dangerous cargo, and renovating during differentiation and development, genomic prevention damage [12]. However, more and more evidence indicated that autophagy could also help tumor occurrence, maintenance, and development [13]. In pancreatic cancer [14], autophagy is a metabolic requirement for cancer cells' immune evasion, allowing tumors to achieve optimal proliferation in vitro and vivo. Besides, autophagy is necessary for tumor cell migration and metastasis because its inhibition will block cell migrates and metastasis [15]. In HCC, autophagy can promote tumor cells' metastasis by upregulating the expression of MCT1 and the activation of the Wnt/β-catenin signaling pathway [16]. The epithelial-mesenchymal can also be activated by autophagy to promote cancer cell invasion [17]. Thus some researchers have tried to find new targeted treatment strategies for HCC by studying autophagy pathways.

Long non-coding RNAs (lncRNAs) are a class of RNA transcripts that consist of more than 200 nucleotides in length and exhibit limited protein-coding capacity [18]. However, With in-depth exploration, IncRNA has been found to perform essential functions in various biological processes such as post-transcriptional regulation, transcriptional regulation, and chromatin modification [19]. Some studies have also reported that lncRNAs regulate many aspects of cancer progression and affect different malignant behaviors, such as cancer cell proliferation, apoptosis, and metastasis [20, 21]. Remarkably, owing to the complexity and diversity, IncRNA's abnormal expression will promote the occurrence of a variety of tumors, such as cervical cancer [22], esophageal squamous cell carcinoma [23], and lung adenocarcinoma [24]. Autophagy has been considered to play a dual and contradictory role in carcinogenesis, and this exact mechanisms that result in autophagy in cancer still need to be further explored [25]. IncRNA participates in the occurrence, invasion, metastasis, prognosis, and chemoresistance of HCC by regulating various pathways related to autophagy [26–28]. However, these studies only concentrated on single or a few IncRNAs for HCC. Although some studies have explored the impact of autophagy-related IncRNAs on the prognosis of HCC patients and constructed predictive signatures, the accuracy of each signature is different and the IncRNAs included are not all the same [29–32]. Therefore, are there other autophagy-related IncRNAs that affect the prognosis of HCC patients? Compared with traditional features, how accurate is the prognosis prediction signature based on these IncRNAs? Is the signature based on HCC patients also applicable to intrahepatic cholangiocarcinoma (ICC) patients? What are the important biological functions of these IncRNAs and what signal transduction pathways do they participate in? These are the questions that our research needs to explore.
Materials and methods
Data obtaining and processing
The entire sequencing profile data of patients with liver hepatocellular carcinoma (HCC) were obtained from The Cancer Genome Atlas (TCGA, https://cancergenome.nih.gov/) database. According to the gene annotations from the GENCODE project (https://www.gencodegenes.org/) [33], the lncRNA and protein-coding gene profile data were further classified. Besides, the patient’s corresponding clinical information was downloaded from the TCGA database, such as survival time, survival status, age, gender, tumor grade, and TNM stage. Moreover, other special clinical features of HCC including prothrombin time (PT), bilirubin, albumin, AFP and Child–Pugh grade were obtained as well. Based on the previously study of Johnson et al. [34], the Albumin–Bilirubin (ALBI) score was also considered into this study to further assess the performance advantage of our constructed signature. ALBI score (As) is calculated as = (log10 bilirubin * 0.66) + (−0.085 * albumin), where bilirubin is in umol/L and albumin in g/L, ALBI grade 1: 0 ≤ −2.6, ALBI grade 2: −2.6 < As ≤ −1.39, and ALBI grade 3: As > −1.39. And then, the HCC patients with incomplete clinical information and survival time that less than 30 days were removed. The sequencing data and clinical information of patients with intrahepatic cholangiocarcinoma (ICC) were obtained and processed in the same way. Since all of these data involved in this study were publicly available, the ethics committee has no specific ethical approval.

Screening of autophagy-related lncRNAs
A list of the autophagy-related genes was downloaded from the Human Autophagy Database (HADb, http://www.autophagy.lu/). The autophagy gene expression profile was extracted from the fore mentioned protein-coding gene profile data. To identify the potential lncRNA related to autophagy-related genes, we performed a Pearson correlation analysis in the lncRNA and autophagy-related gene expression profile by “limma” package [35]. The thresholds were set as follows: |R| > 0.4 and P < 0.001 were considered a strong correlation.

Identify prognosis-related autophagy lncRNAs and calculate the risk score
To confirm the potential prognostic value of autophagy-related lncRNAs, based on the “survival” package [36], univariate Cox regression analysis and product-limit method (Kaplan–Meier method) were used to assess the association between autophagy-related lncRNA expression and survival data. Those autophagy-related lncRNAs are significantly related to survival (Both Kaplan–Meier method and univariate Cox regression satisfy P value < 0.01) were obtained as prognosis-related lncRNAs. Those prognosis-autophagy-related lncRNAs were then used into multivariate Cox regression analysis to obtain regression coefficients (β) with the lowest Akaike information criterion (AIC) values and then establish a risk score. The risk score calculation based as follows = βlnRNA1 × ExpressionlnRNA1 + βlnRNA2 × ExpressionlnRNA2 + ... + βlnRNAn × ExpressionlnRNAn. According to the median risk score, the patients of HCC and ICC were classified into high-risk and low-risk groups.
respectively to further assess whether this signature of risk score is suitable for two types of liver cancer. The “pheatmap” [37] package was utilized to draw the survival status of HCC patients and the heatmap of lncRNA expression based on risk scores grade.

**Analysis of risk score model**

According to the "survival" package, the univariate and multivariate Cox regression analysis were utilized to evaluate whether the risk score of the autophagy-related lncRNAs can be an independent indicator for the prognosis of HCC. And then, based on “survivalROC” [38] package, the receiver operating characteristic (ROC) curve and area under the ROC curve (AUC value) were performed to evaluate diagnostic efficacy of risk score compared with the traditional clinical features (child_pugh, ALBI, APF, TNM stage, stage, grade, PT, bilirubin, and albumin) in HCC and ICC patients. In order to further evaluate the performance advantage in our signature, the "survivalROC" package was used to calculate the AUC values of 1-, 2-, 3-, 4- and 5- year both in our signature and the previously published lncRNAs signature in HCC 06-09, and plot the results through the "ggplot2" package [39].

**Evaluation and construction of Nomogram**

Based on the result of multivariate Cox regression analysis, the “survival” and “rms” [40] packages were utilized to construct a Nomogram which can predict survival probability of HCC patients by the combination of risk score and clinical data. And then, the Bootstrap self-sampling method was repeated 1000 times to evaluate whether the consistency of the predicted results and the actual results by the internal validation method. The difference between the predicted results of the nomogram and the actual results were drew in the calibration curve. Finally, calculated the time dependent ROC curves and the AUC values of this Nomogram.

**Functional analysis**

To further explore the Gene Ontology (GO) [41] and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways [42], these prognostic autophagy-related lncRNAs may participate. We performed Pearson correlation analysis in the final prognostic autophagy-related lncRNA and protein-coding gene profile data. The thresholds were set as follows: $|R| > 0.4$ and $P < 0.001$. Then we analyzed those co-expressed genes with prognostic autophagy-related lncRNAs through the “clusterProfiler” [43] package to speculate the pathways and biological processes that lncRNA may participate in.

**Result**

**Acquisition of autophagy-related lncRNAs**

A total of 147 patients with complete clinical information, 14,748 lncRNAs, and 19,767 mRNA were screened from the TCGA-HCC. In the TCGA-ICC dataset, there were 36 patients have complete survival data. Moreover, 232 autophagy genes were obtained from HADb database, among which 213 genes were expressed in TCGA-HCC. Finally, a total of 557 autophagy-related lncRNAs were identified from TCGA-HCC according to the Pearson correlation analysis with the screening criteria of $|R| > 0.4$ and $P < 0.001$ (Additional file 1: Table S1).
The prognostic autophagy-related lncRNA

According to univariate Cox regression analysis and product-limit method (P value < 0.01), 39 autophagy-related IncRNAs which related to prognostic have been selected (Additional file 2: Table S2). Subsequently, seven autophagy-related IncRNAs that had a co-expression relationship with 65 autophagy genes were identified as robust independent prognostic factors after Multivariate Cox regression (Fig. 1). Among them, PRRT3-AS1 (HR 1.1028, 95% CI 1.0284–1.1827), RP11-479G22.8 (HR 1.0936, 95% CI 1.0261–1.1656), RP11-73M18.8 (HR 1.0635, 95% CI 1.0070–1.1233), LINC01138 (HR 1.2752, 95% CI 1.0110–1.6085), CTD-2510F5.4 (HR 1.1355, 95% CI 1.0607–1.2157), and RP11-324I22.4 (HR 1.2956, 95% CI 1.0181–1.6488) were unfavorable prognostic factors, and the CTC-297N7.9 (HR 0.577, 95% CI 0.3363–0.9900) was beneficial prognostic factor (Fig. 2 and Table 1). The risk score of each HCC patient = (0.0979*PRRT3-AS1) + (0.0896*RP11-479G22.8) + (0.0616*RP11-73M18.8) + (0.2431*LINC01138) + (0.1271*CTD-2510F5.4) + (− 0.5400*CTC-297N7.9).
Based on the risk score, the overall survival (OS) curves indicates that the OS of the high-risk group for HCC patients was significantly shorter than the low-risk group ($P = 2.292 \times 10^{-10}$) (Fig. 3a). The five years survival rate of the high-risk group (HR 0.286, 95% CI 0.199–0.411) is less than half of the low-risk group (HR 0.694, 95% CI 0.547–0.77). Similarly, the distributions of survival status also indicated that the survival rate and time of HCC high-risk group are significantly lower than the low-risk group (Fig. 3d, e), and the expression of 6 unfavorable prognostic factors (PRRT3-AS1, RP11-479G22.8, RP11-73M18.8, LINC01138, CTD-2510F5.4, and RP11-324I22.4) is increased with the risk score increases; on the contrary, the expression of beneficial prognostic factor (CTC-297N7.9) is decreased (Fig. 3c). However, the signature constructed by the sequencing data of HCC patients is deed not suitable for ICC patients, because the OS curve indicates that there is no difference in OS between ICC patients in the high- and low-risk groups ($P = 4.301 \times 10^{-1}$) (Fig. 3b).

**Clinical value of the prognostic autophagy-related IncRNA**

To evaluate whether the seven autophagy-related IncRNAs could be used as the independent prognosis biomarkers of patients in HCC, Univariate cox regression analysis, and Multivariate cox regression analysis were utilized to evaluate the relationship between the clinical data and risk score. Univariate Cox regression indicated that T ($P = 0.005$, 95% CI 1.167–2.372), M ($P = 0.001$, 95% CI 2.222–24.721), Stage ($P = 0.002$, 95% CI 1.227–2.490), Grade ($P = 0.01$, 95% CI 1.173–3.249), PT ($P = 0.024$, 95% CI 1.010–1.157), Tbil ($P = 0.016$, 95% CI 0.683–0.961), risk score ($P < 0.001$, 95% CI 1.224–1.528) were related to the prognosis (Fig. 4a and Table 2). However, after implying multivariate analysis, only the risk score ($P < 0.001$, 95% CI 1.371–1.955), Age ($P = 0.007$, 95% CI 1.012–1.081), M ($P = 0.035$, 95% CI 1.135–34.011), Grade ($P < 0.001$, 95% CI 1.735–7.401), child_pugh ($P = 0.015$, 95% CI 1.389–20.690) were associated with prognosis (Fig. 4b and Table 2). Next, the receiver operating characteristic (ROC) curves were utilized to evaluate the risk score’s predictive performance. In HCC group, the area under the ROC (AUC) curve of risk score for 3-years is 0.786 (Fig. 4c), however, the AUC of ALBI, AFP, and Child–Pugh are only 0.532, 0.571, and 0.573 respectively. Similarly, the AUC of risk score for 3-years is only 0.505 in ICC group as well (Fig. 4d). In the predict performance comparison of multiple

| Table 1 The HR, 95% CI of HR, and $P$ value of the 7 autophagy-related IncRNA based on the multivariate Cox regression analysis |
|---------------------------------|--------|-----------------|-------|
| Name                            | HR     | 95% CI of HR    | $P$ value |
| PRRT3-AS1                       | 1.1028 | 1.0284–1.1827   | 0.0061  |
| RP11-479G22.8                   | 1.0936 | 1.0261–1.1656   | 0.0059  |
| RP11-73M18.8                    | 1.0635 | 1.0070–1.1233   | 0.0272  |
| LINC01138                       | 1.2752 | 1.0110–1.6085   | 0.0401  |
| CTD-2510F5.4                    | 1.1355 | 1.0607–1.2157   | 0.0003  |
| CTC-297N7.9                     | 0.577  | 0.3363–0.9900   | 0.0459  |
| RP11-324I22.4                   | 1.2956 | 1.0181–1.6488   | 0.0352  |

HR hazard ratio
signatures, the predict performance of our constructed signature is superior to the previously published 4 lncRNA-related signature in HCC (Fig. 4, Table 3).

Evaluation of the nomogram
Based on previous multivariate Cox regression analysis, the risk score, M_stage, child_pugh, age, and Grade were both independent prognostic factors. Therefore, all of these factors were adopted into a nomogram which can assist in clinical interpretation of the
constructed signature and be convenient to predict the survival rate of HCC patients. Based on the nomogram, the survival rate of 1- and 3-years can be assessed by summing the score of each item (Fig. 5a). The calibration curves of the nomogram indicates that the predicted survival rates of 1- and 3- years have superior accuracy (Fig. 5b, c). The area under the ROC curve (AUC) are 0.87, and 0.855 respectively (Fig. 5d, e).

Functional analysis
Under the inclusion criteria of $|R| > 0.4$ and $P < 0.001$, a total of 3580 genes that have a co-expression relationship with 7 prognostic autophagy-related IncRNAs were obtained (Additional file 3: Table S3). KEGG analysis shows that the 7 IncRNAs are directly or indirectly involved in Spliceosome, Cell cycle, RNA transport, DNA replication, Ribosome, mRNA surveillance pathway, and Endocytosis (Fig. 6b). GO results indicate that these IncRNAs may be related to the biological process of RNA splicing, mRNA splicing, RNA localization, covalent chromatin modification, and histone modification (Fig. 6a).

Discussion
Autophagy, an evolutionary and conservative multistage lysosomal degradation process that promotes metabolism and healthy circulation, plays a complex and contradictory role in tumor formation and cancer treatment [11]. As a subclass of the ncRNAs family, IncRNAs play an indispensable role in various biological processes of tumorigenesis, which are considered a new type of biomarker for cancer diagnosis and prognosis widely
concerned [44]. Although some studies have explored the impact of autophagy-related lncRNAs on the prognosis of HCC patients and constructed predictive signatures, the accuracy of each signature is different and the lncRNAs included are not all the same. Therefore, it is necessary to explore more autophagy-related lncRNAs that affect the prognosis of HCC patients to further discover specific regulatory networks.

In our study, autophagy-related lncRNAs were obtained by establishing the co-expression network of lncRNAs and autophagy genes. Univariate and multivariate Cox regression analyses were used to obtain the 7 prognostic autophagy-related lncRNAs, including PRRT3-AS1, RP11-479G22.8, RP11-73M18.8, LINC01138, CTD-2510F5.4, and RP11-324I22.4, and CTC-297N7.9. The analysis of the signature constructed by these 7 lncRNAs shows that this risk score has good survival prediction efficiency in HCC patients ($P = 2.292 \times 10^{-10}$). Compared with traditional factors ALBI (AUC is 0.532), child_pugh (AUC is 0.573), Stage (AUC is 0.631) and AFP (AUC is 0.571), the forecasting advantage of risk score is significant (AUC is 0.786). On the contrary, the prognostic prediction value of the risk score in the ICC patient group is not obvious enough.

### Table 2 Clinical characteristics and risk scores based on Univariate and multiple Cox regression analysis

| Type          | B    | SE   | z     | HR   | 95% CI of HR | P value |
|---------------|------|------|-------|------|--------------|---------|
| **Univariate Cox regression analysis** |      |      |       |      |              |         |
| Age           | 0.016| 0.014| 1.135 | 1.016| 0.988–1.045  | 0.256   |
| Gender        | 0.585| 0.351| 1.667 | 0.557| 0.280–1.110  | 0.096   |
| T             | 0.509| 0.181| 2.815 | 1.664| 1.167–2.372  | 0.005   |
| M             | 2.003| 0.615| 3.259 | 7.411| 2.222–24.721 | 0.001   |
| Stage         | 0.559| 0.180| 3.095 | 1.748| 1.227–2.490  | 0.002   |
| Grade         | 0.669| 0.260| 2.573 | 1.952| 1.173–3.249  | 0.010   |
| PT            | 0.078| 0.035| 2.253 | 1.081| 1.010–1.157  | 0.024   |
| Tbil          | 0.210| 0.087| 2.413 | 0.810| 0.683–0.961  | 0.016   |
| Alb           | 0.001| 0.016| 0.052 | 1.001| 0.969–1.034  | 0.959   |
| ALBI          | 0.136| 0.300| 0.453 | 1.146| 0.636–2.065  | 0.651   |
| AFP           | 0.210| 0.380| 0.552 | 1.233| 0.585–2.599  | 0.581   |
| child_pugh    | 0.791| 0.491| 1.613 | 2.206| 0.843–5.772  | 0.107   |
| Risk score    | 0.313| 0.057| 5.520 | 5.520| 1.224–1.528  | <0.0001 |
| **Multiple Cox regression analysis** |      |      |       |      |              |         |
| Age           | 0.045| 0.017| 2.708 | 1.046| 1.012–1.081  | 0.007   |
| Gender        | 0.515| 0.448| 1.150 | 0.597| 0.248–1.438  | 0.250   |
| T             | 0.063| 0.561| 0.112 | 0.939| 0.313–2.818  | 0.911   |
| M             | 1.827| 0.867| 2.106 | 6.214| 1.135–34.011 | 0.035   |
| Stage         | 0.651| 0.575| 1.133 | 1.918| 0.622–5.917  | 0.257   |
| Grade         | 1.276| 0.370| 3.448 | 3.583| 1.735–7.401  | 0.001   |
| PT            | 0.055| 0.061| 0.914 | 0.946| 0.840–1.065  | 0.361   |
| Tbil          | 0.072| 0.118| 0.612 | 0.931| 0.739–1.172  | 0.541   |
| Alb           | 0.016| 0.032| 0.514 | 1.016| 0.955–1.081  | 0.607   |
| ALBI          | 0.741| 0.579| 1.280 | 2.098| 0.674–6.528  | 0.201   |
| AFP           | 0.485| 0.457| 1.062 | 1.062| 0.616–1.507  | 0.288   |
| child_pugh    | 1.679| 0.689| 2.437 | 5.362| 1.389–20.690 | 0.015   |
| Risk score    | 0.493| 0.091| 5.438 | 1.637| 1.371–1.955  | <0.0001 |

The bold means these clinical features are statistically significant in the Univariate- or Multivariate-cox regression analysis.
### Table 3  Performance evaluation among 5 lncRNAs-related prognostic prediction models for HCC patients

| Signature               | Risk score                                                                                      | The AUC value | 1-year | 2-year | 3-year | 4-year | 5-year |
|-------------------------|-------------------------------------------------------------------------------------------------|---------------|--------|--------|--------|--------|--------|
| 7-lncRNAs (Our study)  | Risk score = (0.0979 × PRRT3-AS1) + (0.0896 × RP11-479G22.8) + (0.0616 × PR11-73M18.8) + (0.2431 × LINC01138) + (0.1271 × CTD-2510F5.4) + (0.5400 × CTC-297N7.9) + (0.2590 × RP11-32422.4) |               | 0.826  | 0.772  | 0.785  | 0.783  | 0.762  |
| 7-lncRNAs (Liu's study)| Risk score = (0.3563 × AC005229.4) + (0.2680 × AL365203.2) + (0.3230 × AL1117336.3) + (0.2081 × AC099850.3) + (0.2852 × ELF1-AS1) + (0.2428 × LUCAT1) + (0.5044 × AL031985.3) |               | 0.773  | 0.751  | 0.751  | 0.743  | 0.736  |
| 5-lncRNAs (Yang's study)| Risk score = (CYTOR × 0.17456) + (LINC011063 × 0.30093) + (MCILN1-AS × 0.27462) + (PL851-AS1 × 0.17218) + (TMCC1-AS1 × 0.28974) |               | 0.740  | 0.742  | 0.722  | 0.718  | 0.701  |
| 4-lncRNAs (Zhu's study)| Risk score = (0.125 × AC0099850.3) + (0.305 × LUCAT1) + (0.055 × ZFPM2-AS1) + (0.106 × AC0039003.1) |               | 0.709  | 0.700  | 0.714  | 0.718  | 0.716  |
| 4-lncRNAs (Tao's study)| Risk score = (0.2567 × RP11-322E11.5) + (0.1307 × RP11-150O12.3) + (−0.2320 × AC093609.1) + (−0.1857 × CTC-297N7.9) |               | 0.798  | 0.748  | 0.749  | 0.726  | 0.734  |

This table covers the linear calculation formula and the AUC value within 1- to 5- years of each signature.
Moreover, the nomogram shows that the 1-year and 3-year survival rates of patients are obviously accuracy by the combined analysis of the risk score, child_pugh, age, M-stage, and Grade (The AUC of 1 and 3-years are 0.87, and 0.855). Therefore, the seven autophagy-related lncRNAs which constructed signature may become potential prognostic molecular markers and therapeutic targets for HCC patients.

On the one hand, as the only beneficial prognostic lncRNA in the prognostic prediction model, the gene alias of CTC-297N7.9 is Inc-TMEM220-1, which is an intergenic ncRNA. An HCC study showed that CTC-297N7.9 might be related to cofactor/
chromatin/NAD binding and oxidoreductase/DNA-dependent ATPase activity [45]. Besides, due to the specific low expression and high methylation of TMEM220 in gastric cancer tissues [46], some scholars speculate that CTC-297N7.9 that located upstream of the protein-coding gene TMEM220, may be able to regulate the methylation of TMEM220 or participate in autophagy through its functional proteins, which in turn affects the prognosis of HCC patients [32]. In our research, we have speculated that the highly expressed CTC-297N7.9 may be an inhibitory factor in the progression of HCC. This speculation was confirmed in another study on liver cancer, and the high expression of CTC-297N7.9 often predicts better overall survival and disease-free survival [47] and indicates that CTC-297N7.9 may be one of the critical molecules to improve HCC patients’ survival, and it can be further explored in subsequent studies on HCC.

On the other hand, the 6 unfavorable prognostic IncRNAs in the prognostic prediction model have also been attached to various cancers. The official full name of PRRT3-AS1 is PRRT3 antisense RNA 1, as a non-protein-coding RNA, which is mainly expressed in liver tissue (RPKM 0.15), fat (RPKM 4.4), prostate (RPKM 3.3), and brain tissue (RPKM 3.0) [48]. In prostate cancer, Fan et al. confirmed that PRRT3-AS1 has a targeting relationship with PPARγ. Its silence can promote apoptosis autophagy and inhibit the proliferation, migration, and invasion of tumor cells through the mTOR signaling pathway [49]. Besides, PRRT3-AS1 is also considered to be related to GBM patients’ prognosis [50]. RP11-479G22.8 is also known as Inc-ITGB1-1 in the LNCipedia database [51], and its transcription size is 2051 bp. Through the IncRNA disease prediction module of the IncRNASNP2 database [52], RP11-479G22.8 is closely related to HCC ($P < 0.001$). Therefore, RP11-479G22.8 is expected to be one of the potential indicators for prognostic prediction in HCC patients [45]. RP11-73M18.8 is a sense-intronic IncRNA with a transcript size of 811 bp, also known as Inc-ZFYVE21-3. Sense-intronic IncRNA is a sequence in the intron of the coding gene on the sense strand. It might harbor different...
histone modification at the transcription start site (TSS) than other ncRNAs [53], which indicated that these intronic lncRNAs maybe the novel biomarkers, such as type 2 diabetes mellitus [54]. LINC01138 is also a member of the sense intron ncRNA, located on chr1. Its abnormal expression has an important influence on the occurrence and development of several cancers. In prostate cancer (PCa), as a lncRNA that directly target AR, the high expression of LINC01138 can promote the proliferation of tumor cells and inhibit their apoptosis, which indicated that LINC01138 could be a diagnostic and prognostic marker for PCa [55]. Besides, LINC01138 can increase the arginine methylation and protein stability of sterol regulatory element-binding protein one by interacting with PRMT5, thereby promoting lipid desaturation and cell proliferation in clear cell renal cell carcinoma and being associated with poor prognosis [56]. However, the knockdown of LINC01138 can inhibit the viability, proliferation, invasion, and migration and promotes apoptosis of gastric cancer cells through the LINC01138/miR-1273e/MAPK axis [57]. In some studies related to HCC, high-expressed LINC01138 is not only significantly associated with poor survival [58] but also can interact with arginine methyltransferase 5 to promote cell proliferation, tumorigenicity, tumor invasion, and metastasis [59]. CTD-2510F5.4 is a 321 bp antisense lncRNA, also known as Inc-SKA2-1 in the LNCipedia database. Through the NPInterv4.0 database [60], we found that CTD-2510F5.4 mainly interacts with genes in the mRNA surveillance pathway and RNA transport pathway. The high expressed CTD-2510F5.4 also has a significant co-expression relationship with mRNAs of the cell cycle, DNA replication, and p53 signaling pathway [61]. It is closely related to the poor prognosis of patients with lung adenocarcinoma [62]. In gastric cancer, the highly expressed CTD-2510F5.4 may be an independent risk factor for tumors with pathological grade <III and no vascular or nerve infiltration [63]. RP11-324I22.4 is an antisense lncRNA; the gene alias is Inc-CUL2-3. As cancer or tumor suppressor genes, antisense IncRNAs play an essential role in the occurrence and development of human cancer [64–66]. Although there is currently no disease research related to RP11-324I22.4, antisense IncRNAs may certainly be the promising tumor biomarker and therapeutic target in future research.

Although the constructed signature shows superiority in predicting the prognosis of HCC patients compared with traditional indicators (ALBI, APF, child_pugh, and Stage) and the previously published signatures, there are still certain limitations. This study is only based on the TCGA database, and there are no suitable datasets in GEO (Gene Expression Omnibus, https://www.ncbi.nlm.nih.gov/geo/) [67] and ICGC (International cancer genome consortium, https://dcc.icgc.org/) [68] databases to verify the risk prediction signature. Furthermore, the research is only conducted at the level of bioinformatics; a comprehensive in vitro experiment is needed further to explore the regulatory mechanism of these autophagy IncRNAs.

Conclusions
In general, the constructed risk prediction model of autophagy-related IncRNAs (PRRT3-AS1, RP11-479G22.8, RP11-73M18.8, LINC01138, CTD-2510F5.4, and RP11-324I22.4, and CTC-297N7.9) based on autophagy genes is robust and promising. The IncRNAs in this model can be used as potential biomarkers for the prognosis of HCC, which will help the individualized treatment of HCC.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12859-021-04123-6.

Additional file 1: Table S1. The co-expression result of autophagy-related lncRNAs and autophagy genes.

Additional file 2: Table S2. The 39 strong prognostic autophagy-related lncRNAs were identified by univariate Cox regression analysis and product-limit method.

Additional file 3: Table S3. The 3580 genes have co-expression with 7 prognostic autophagy-related lncRNAs.

Acknowledgements
Not applicable.

Authors’ contributions
SY and YZ contribute equally. LY and LW contributed to the conception and design of the study. LY and XZ organized the database and statistical analysis for the first manuscript. LY and YZ wrote the first draft of the manuscript. SY, YZ and XZ organized the database and statistical analysis for the revised manuscript. XZ and SY performed visualizations. SY and YZ contributed to the major revised manuscript. XZ, JF, XTZ, LW and LY contributed to partial manuscript revision. LY and LW acted as corresponding author. All the authors read and approved the final manuscript.

Funding
The design, the collection, analysis, interpretation of data, and the writing of the manuscript were supported in part by the special scientific research project of health young medical science and technology talents in Xinjiang Uygur Autonomo us Region (WYYW-202010).

Availability of data and materials
The entire sequencing profile data and the clinical data of HCC and ICC patients in this study come from The Cancer Genome Atlas (TCGA, https://cancergenome.nih.gov/) database, and the autophagy-related genes were obtained from Human Autophagy Database (HADb, http://www.autophagy.lu/).

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Shandong Second Provincial General Hospital, Shandong, China. 2 Shihezi University School of Medicine, Shihezi, China. 3 The First Affiliated Hospital of Shihezi University School of Medicine, Shihezi, China. 4 Clinical Laboratory Diagnosis Center, General Hospital of Xinjiang Military Region, Xinjiang, China. 5 Department of Medical Laboratory Science, Xinjiang Bayingoleng Mongolian Autonomous Prefecture People’s Hospital, Xinjiang, China.

Received: 23 December 2020   Accepted: 5 April 2021

Published online: 28 April 2021

References
1. Berndt N, et al. Characterization of lipid and lipid droplet metabolism in human HCC. Cells. 2019;8(5):512.
2. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
3. Pei Y, et al. An overview of hepatocellular carcinoma study by omics-based methods. Acta Biochim Biophys Sin (Shanghai). 2009;41(1):1–15.
4. Fitzmorris P, et al. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2015;141(5):861–76.
5. Chen S, et al. Targeted therapy for hepatocellular carcinoma: challenges and opportunities. Cancer Lett. 2019;4601–9.
6. Zheng T, et al. Safety and long-term outcomes of anatomic left hepatic trisectionectomy for intermediate and advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2015;30(6):1015–23.
7. Tian M, et al. Gene-environment interactions between GSTs polymorphisms and targeted epigenetic alterations in hepatocellular carcinoma following organochlorine pesticides (OCPs) exposure. Environ Int. 2020;134:105313.
8. Li WT, et al. Etiology-specific analysis of hepatocellular carcinoma transcriptome reveals genetic dysregulation in pathways implicated in immunotherapy efficacy. Cancers (Basel). 2019;11(9):1273.
9. Lim LJ, et al. Roles and regulation of long noncoding RNAs in hepatocellular carcinoma. Cancer Res. 2019;79(20):5131–9.
10. Harris WP, et al. Biomarker-driven and molecular targeted therapies for hepatobiliary cancers. Semin Oncol. 2018;45(3):116–23.
11. Amaravadi RK, Kimmelman AC, Debnath J. Targeting autophagy in cancer: recent advances and future directions. Cancer Discov. 2019;9(9):1167–81.
12. Levine B, Kroemer G. Biological functions of autophagy genes: a disease perspective. Cell. 2019;176(1–2):11–42.
13. Towers CG, Wodetzki D, Thorburn A. Autophagy and cancer: modulation of cell death pathways and cancer cell adaptations. J Cell Biol. 2020;219(1):e201909033.
14. Zhu XG, et al. Functional genomics in vivo reveal metabolic dependencies of pancreatic cancer cells. Cell Metab. 2021;33(1):211-221.e6.
15. Sharifi MN, et al. Autophagy promotes focal adhesion disassembly and cell motility of metastatic tumor cells through the direct interaction of Paxillin with LC3. Cell Rep. 2016;15(8):1660–72.
16. Fan Q, et al. Autophagy promotes metastasis and glycolysis by upregulating MCT1 expression and Wnt/beta-catenin signaling pathway activation in hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2018;37(1):9.
17. Li J, et al. Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelial-mesenchymal transition. Carcinogenesis. 2013;34(6):1343–51.
18. Evans JR, Feng FY, Chinnaiyan AM. The bright side of dark matter: lncRNAs in cancer. J Clin Invest. 2016;126(8):2775–82.
19. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–9.
20. Beermann J, et al. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev. 2016;96(4):1297–325.
21. Prensner JR, Chinnaiyan AM. The emergence of IncRNAs in cancer biology. Cancer Discov. 2011;1(5):391–407.
22. Galvao M, Coimbra EC. Long non-coding RNAs (lncRNAs) in cervical carcinogenesis: new molecular targets, current prospects. Crit Rev Oncol Hematol. 2020;166:103111.
23. Wang Z, et al. A novel long noncoding RNA, LOC440173, promotes the progression of esophageal squamous cell carcinoma by modulating the miR-30d-5p/HDAC9 axis and the epithelial-mesenchymal transition. Mol Carcinog. 2020;59(12):1392–408.
24. Zhao M, et al. LncRNA GMD5-AS1 inhibits lung adenocarcinoma development by regulating miR-96-5p/CDYLD signaling. Cancer Med. 2020;9(3):1196–208.
25. Dower CM, et al. Mechanisms and context underlying the role of autophagy in cancer metastasis. Autophagy. 2018;14(7):1110–28.
26. Zhang Z, et al. Long non-coding RNA ADAMTS9-AS1 exacerbates cell proliferation, migration, and invasion via triggering of the PI3K/Akt/mTOR pathway in hepatocellular carcinoma cells. Am J Transl Res. 2020;12(9):5696–707.
27. Peng N, et al. Long noncoding RNA MALAT1 inhibits the apoptosis and autophagy of hepatocellular carcinoma cell by targeting the microRNA-146a/PI3K/Akt/mTOR axis. Cancer Cell Int. 2020;20:165.
28. Zhang W, et al. Long non-coding RNA LINCO0160 functions as a decoy of microRNA-132 to mediate autophagy and drug resistance in hepatocellular carcinoma via inhibition of PI3K/R. Cancer Lett. 2020;478:22–33.
29. Jia Y, Chen Y, Liu J. Prognosis-predictive signature and nomogram based on autophagy-related lncRNA for hepatocellular carcinoma. Front Genet. 2020;11:608668.
30. Deng X, et al. Identification of a five-autophagy-related-lncRNA signature as a novel prognostic biomarker for hepatocellular carcinoma. Front Mol Biosci. 2020;7:611626.
31. Wu H, et al. Four autophagy-related lncRNAs predict the prognosis of HCC through coexpression and ceRNA mechanism. Biomed Res Int. 2020;2020:3801748.
32. Wang Z, et al. Identification of four prognostic lncRNAs for survival prediction of patients with hepatocellular carcinoma. PeerJ. 2017;5:e3575.
33. Derrien T, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–89.
34. Johnson PJ, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550–8.
35. Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
36. Therneau T. A Package for Survival Analysis in R. R package version 3.2-7. 2020. https://CRAN.R-project.org/package=survival. Accessed 17 Mar 2021.
37. Raivo K. pheatmap: Pretty Heatmaps. R package version 1.0.12. 2019. https://CRAN.R-project.org/package=pheatmap. Accessed 17 Mar 2021.
38. Patrick J. Heagerty and packaging by Paramita Saha-Chaudhuri. survivalROC: Time-dependent ROC curve estimation from censored survival data. R package version 1.0.3. 2013. https://CRAN.R-project.org/package=survivalROC. Accessed 17 Mar 2021.
39. Campitelli E. Ggnewscale: Multiple Fill and Colour Scales in ‘Ggplot2’. 2020. https://CRAN.R-project.org/package=ggnewscale. Accessed 17 Mar 2021.
40. Harrell FE Jr. rms: Regression Modeling Strategies. R package version 6.1-0. 2020. https://CRAN.R-project.org/package=rms. Accessed 17 Mar 2021.
41. Kanehisa M, et al. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49:D545–51.
47. Zhu S, et al. Low expression of long noncoding RNA CTC-297N7.9 predicts poor prognosis in patients with hepatocellular carcinoma. Cancer Med. 2019;8(18):7679–72.
48. Fagerberg L, et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics. 2014;13(2):397–406.
49. Fan L, Li H, Wang W. Long non-coding RNA PRR3-AS1 silencing inhibits prostate cancer cell proliferation and promotes apoptosis and autophagy. Exp Physiol. 2020;105(5):793–808.
50. Liang R, et al. Analysis of long non-coding RNAs in glioblastoma for prognosis prediction using weighted gene co-expression network analysis, Cox regression, and L1-LASSO penalization. Onco Targets Ther. 2019;12:157–68.
51. Volders PI, et al. LNCipedia S: towards a reference set of human long non-coding RNAs. Nucleic Acids Res. 2019;47(D1):D155–9.
52. Miao YR, et al. IncRNASNPv2: an updated database of functional SNPs and mutations in human and mouse lncRNAs. Nucleic Acids Res. 2018;46(D1):D276–80.
53. Ghosh S, et al. Distinct patterns of epigenetic marks and transcription factor binding sites across promoters of sense-intronic long noncoding RNAs. J Genet. 2015;94(1):17–25.
54. Anbari DM, Al-Harithy RN. Ghrelin intronic lncRNAs, Inc-GHRL-3.2 and Inc-GHRL-3.3, as novel biomarkers in type 2 diabetes mellitus. Arch Physiol Biochem. 2020;1–5.
55. Han X, et al. Identification of androgen-responsive IncRNAs as diagnostic and prognostic markers for prostate cancer. Oncotarget. 2016;7(37):60503–18.
56. Zhang X, et al. The LINC01138 interacts with PRMT5 to promote SREBP1-mediated lipid desaturation and cell growth in clear cell renal cell carcinoma. Biochem Biophys Res Commun. 2018;507(1–4):337–42.
57. Dou GX, et al. Long intergenic non-protein-coding RNA 01138 accelerates tumor growth and invasion in gastric cancer by regulating miR-1273e. Med Sci Monit. 2019;25:2141–50.
58. Jiang H, et al. Up-regulated long non-coding RNA DUXAP8 promotes cell growth through repressing Kruppel-like factor 2 expression in human hepatocellular carcinoma. Onco Targets Ther. 2019;12:7429–36.
59. Li Z, et al. The LINC01138 drives malignancies via activating arginine methyltransferase S in hepatocellular carcinoma. Nat Commun. 2018;9(1):1572.
60. Teng X, et al. NPInterv4.0: an integrated database of ncRNA interactions. Nucleic Acids Res. 2020;48(D1):D160–5.
61. Wang Y, et al. Screening key IncRNAs for human lung adenocarcinoma based on machine learning and weighted gene co-expression network analysis. Cancer Biomark. 2019;25(4):313–24.
62. Wang X, et al. Integrated TCGA analysis implicates IncRNA CTB-193M12.5 as a prognostic factor in lung adenocarcinoma. Cancer Cell Int. 2018;18:27.
63. Wang Z, Qin B. Prognostic and clinicopathological significance of long noncoding RNA CTD-2510FS.4 in gastric cancer. Gastric Cancer. 2019;22(4):692–704.
64. Da CM, et al. Role of HAND2-AS1 in human tumors. Clin Chim Acta. 2020;511:189–97.
65. Ruan Z, et al. Downregulation of long non-coding RNA MAFG-AS1 represses tumorigenesis of colorectal cancer cells through the microRNA-149-3p-dependent inhibition of HOXB8. Cancer Cell Int. 2020;20:511.
66. Yang J, et al. The long non-coding RNA ZEB2-AS1 contributes to proliferation and epithelial-to-mesenchymal transition of osteosarcoma. Cancer Biother Radiopharm. 2020.
67. Barrett T, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 2013;41(Database issue):D991–5.
68. Zhang J, et al. The International Cancer Genome Consortium data portal. Nat Biotechnol. 2019;37(4):367–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.